Jacobs Bruce N. 4
4 · Kymera Therapeutics, Inc. · Filed Sep 17, 2025
Insider Transaction Report
Form 4
Jacobs Bruce N.
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-09-17$50.00/sh−79,220$3,961,380→ 227,409 total - Exercise/Conversion
Common Stock
2025-09-17$2.08/sh+79,220$164,778→ 306,629 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-17−42,246→ 27,653 totalExercise: $2.08Exp: 2029-08-28→ Common Stock (42,246 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-09-17−36,974→ 0 totalExercise: $2.08Exp: 2029-08-28→ Common Stock (36,974 underlying)
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
- [F2]This number includes 523 shares acquired under the Registrant's employee stock purchase plan on June 2, 2025.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.90 to $50.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The shares underlying this stock option are fully vested and exercisable.